Back to Results
First PageMeta Content
Ivacaftor / Phenols / Quinolones / Cystic fibrosis / Vertex Pharmaceuticals / Clinical trial / VX-809 / Health / Medicine / Anilides


6.11 IVACAFTOR Tablet; 150 mg; Kalydeco®; Vertex Pharmaceuticals (Australia) Pty Ltd. Purpose of Application
Add to Reading List

Document Date: 2015-03-16 01:05:15

Open Document

File Size: 54,64 KB

Share Result on Facebook

Company

Vertex Pharmaceuticals (Australia) Pty Ltd / The PBAC / /

Country

Australia / /

Currency

USD / /

Event

FDA Phase / Reorganization / /

IndustryTerm

treatment of cystic fibrosis / /

MedicalCondition

pulmonary / pulmonary exacerbation Absolute change / cystic fibrosis transmembrane conductance regulator / cystic fibrosis / /

MedicalTreatment

antibiotics / /

Position

Major / /

Product

IVACAFTOR Tablet / Manufacturer IVACAFTOR Tablet / FEV1 / ivacaftor / G551D / /

PublishedMedium

The Commentary / /

RadioStation

CFTR / /

Technology

submission Trial ID Protocol / /

SocialTag